171 related articles for article (PubMed ID: 36755262)
21. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
Lin J; Wang W; Lin J; Chen R; Cao Y
J Cell Mol Med; 2022 Oct; 26(20):5326-5329. PubMed ID: 36102237
[TBL] [Abstract][Full Text] [Related]
22. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
[TBL] [Abstract][Full Text] [Related]
23. Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib.
Chen X; Zhao G; Zhong P; Zhang M; Chen R; Zhang D
Clin Lung Cancer; 2020 Nov; 21(6):e564-e566. PubMed ID: 32576444
[No Abstract] [Full Text] [Related]
24. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
Tian X; Liao Q; Yang Q; Chen L; Xiao M; Cheng Y
Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
[TBL] [Abstract][Full Text] [Related]
25. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
Fei X; Zhu L; Zhou H; Qi C; Wang C
J Thorac Oncol; 2019 Sep; 14(9):e191-e193. PubMed ID: 31445731
[No Abstract] [Full Text] [Related]
26. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
27. ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
Gonzalez-Mosquera LF; Rous FA; Rogers A; Smith N; Goyert G; Gadgeel S
Clin Lung Cancer; 2024 Mar; 25(2):e77-e80. PubMed ID: 38057186
[TBL] [Abstract][Full Text] [Related]
28. [Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report].
Bai H; Han Y; Niu Y; Zhang M
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):598-604. PubMed ID: 34344501
[TBL] [Abstract][Full Text] [Related]
29. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
30. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
Nagasaka M; Fisher A; Chowdhury T; Ge Y; Sukari A
Clin Lung Cancer; 2021 Jan; 22(1):e51-e53. PubMed ID: 32893122
[No Abstract] [Full Text] [Related]
31. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
[TBL] [Abstract][Full Text] [Related]
32. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
[TBL] [Abstract][Full Text] [Related]
33. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
Wu X; Wang W; Zou B; Li Y; Yang X; Liu N; Ma Q; Zhang X; Wang Y; Li D
Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
[TBL] [Abstract][Full Text] [Related]
34. Alectinib relieves ischemic strokes caused by left atrial metastasis in a NSCLC patient with a novel SLC34A2-ALK (exon 1: exon 15) fusion.
Zhou N; Wu M; Yuan M; Wu H; Yu S; Gao X; Wang Y
Lung Cancer; 2023 Sep; 183():107289. PubMed ID: 37542770
[TBL] [Abstract][Full Text] [Related]
35. A novel
Pan X; Zhong A; Xing Y; Li X; Du H; Shi M
J Int Med Res; 2021 Sep; 49(9):3000605211044652. PubMed ID: 34590916
[TBL] [Abstract][Full Text] [Related]
36. An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.
Dou Y; Duan Q; Qi C; Hou L; Wang H
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1865-1867. PubMed ID: 33544200
[TBL] [Abstract][Full Text] [Related]
37. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
38. [A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene].
Yuan Y; Wang Z; Nie X; Zhang P; Li L
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):696-700. PubMed ID: 36172736
[TBL] [Abstract][Full Text] [Related]
39. Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
Wang YL; Wu ZZ; Zhang HR; Chen DS; Zhao X
Lung Cancer; 2021 Apr; 154():216-218. PubMed ID: 33637344
[No Abstract] [Full Text] [Related]
40. A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis.
Cheng W; Qian C; Zhang H; Meng Q; Yin JC; Fang S
Anticancer Drugs; 2022 Nov; 33(10):1182-1185. PubMed ID: 35946559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
